Trials / Conditions / Myeloproliferative Diseases

Myeloproliferative Diseases

11 registered clinical trials studyying Myeloproliferative Diseases — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Unknown	CAR-NK Cells Production and Expansion From Patients With Lympho or Myeloproliferative Disorders and From Healt NCT06727383	European Institute of Oncology	N/A
Recruiting	Investigation of the Genetics of Hematologic Diseases NCT02720679	St. Jude Children's Research Hospital	—
Terminated	Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN) NCT02410551	M.D. Anderson Cancer Center	Phase 2
Completed	Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF) NCT02267278	M.D. Anderson Cancer Center	Phase 2
Terminated	Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene NCT01875237	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Completed	Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning NCT01572662	M.D. Anderson Cancer Center	Phase 2
Terminated	Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT) NCT01518153	M.D. Anderson Cancer Center	Phase 2
Completed	Clofarabine Plus Low-Dose Cytarabine for Patients With Higher-Risk Myelodysplastic Syndrome (MDS) NCT01444742	M.D. Anderson Cancer Center	Phase 2
Completed	Ruxolitinib and Lenalidomide for Patients With Myelofibrosis NCT01375140	M.D. Anderson Cancer Center	Phase 2
Completed	Phase IIA Study of the HDAC Inhibitor ITF2357 in Patients With JAK-2 V617F Positive Chronic Myeloproliferative NCT00606307	Italfarmaco	Phase 2
Completed	Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematolo NCT00513175	University of California, San Francisco	—